|
![spacer](https://webarchive.library.unt.edu/web/20130226140605im_/http://wwwn.cdc.gov/i/s.gif) |
![spacer](https://webarchive.library.unt.edu/web/20130226140605im_/http://wwwn.cdc.gov/i/s.gif) |
![spacer](https://webarchive.library.unt.edu/web/20130226140605im_/http://wwwn.cdc.gov/i/s.gif) |
![spacer](https://webarchive.library.unt.edu/web/20130226140605im_/http://wwwn.cdc.gov/i/s.gif) |
Record of Attendance |
|
Committee Members
|
Ex Officio Members
|
Dr. Toby L. Merlin, Chair |
Dr. Robert Martin |
Dr. George Birdsong |
Dr. Steven Gutman |
Dr. Joseph Campos |
Ms. Judith Yost |
Dr. Patricia Charache |
|
Dr. Brenta Davis |
|
Dr. Andrea Ferreira-Gonzalez |
Liaison Representative |
Dr. Kathryn Foucar |
Ms. Kay A. Setzer, AdvaMed |
Dr. Ronald Gagne |
|
Dr. Cyril (Kim)
Hetsko |
|
Ms. Cynthia Johns |
|
Dr. Ronald Luff |
|
Dr. Valerie Ng |
|
Dr. Timothy O'Leary |
|
Mr. Stewart Lee Richardson |
|
Dr. Lawrence Silverman |
|
Mr. Albert Stahmer |
|
Dr. Lawrence Sturman |
|
Dr. David Sundwall |
|
Dr. Roland Valdes |
|
Dr. Alice Weissfeld |
|
|
|
Centers for Disease Control and Prevention |
Ms. Nancy Anderson |
Dr. Adam Manasterski |
Ms. Diane Bosse |
Ms. Anne Pollock |
Ms. Carol Bigelow |
Ms. Andrea Pratcher |
Dr. Joe Boone |
Ms. Cathy Ramadei |
Dr. Bin Chen |
Dr. Shahram Shahangian |
Ms. Carol Cook |
Mr. Darshan Singh |
Ms. Judy Delany |
Mr. Howard Eric Thompson |
Ms. MariBeth Gagnon |
Ms. Pam Thompson |
Ms. Sharon Granade |
Ms. Glennis Westbrook |
Dr. Tom Hearn |
Ms. Rhonda Whalen
|
Ms. Jerri Holmes |
|
Ms. Stacey Holt |
|
Ms. Helen Kuykendall |
|
Mr. David Lyle |
|
Mr. Kevin Malone |
|
|
|
Department of Health and Human Services
(Agencies other than CDC) |
Ms. Valerie Coppola (CMS) |
Dr. Elliot Cowan (FDA) |
Ms. Cecelia Hinkel (CMS) |
Dr. Joe Hackett (FDA) |
Ms. Ronalda Leneau (CMS) |
Ms. Clara Sliva (FDA) |
Ms. Gwendolyn Williams (CMS) |
|
|
|
Clinical Laboratory
Improvement Advisory Committee
|
The Secretary of Health and Human Services is authorized under Section
353 of the Public Health Service Act, as amended, to establish standards to
assure consistent, accurate, and reliable test results by all clinical
laboratories in the United States. The Secretary is authorized under Section
222 to establish advisory committees.
The Clinical Laboratory Improvement Advisory Committee (CLIAC) was
chartered in February 1992 to provide scientific and technical advice and
guidance to the Secretary and the Assistant Secretary for Health regarding
the need for, and the nature of, revisions to the standards under which
clinical laboratories are regulated; the impact on medical and laboratory
practice of proposed revisions to the standards; and the modification of the
standards to accommodate technological advances.
The Committee consists of 20 members, including the Chair. Members are
selected by the Secretary from authorities knowledgeable in the fields of
microbiology, immunology, chemistry, hematology, pathology, and
representatives of medical technology, public health, clinical practice, and
consumers. In addition, CLIAC includes three ex officio members, or
designees: the Director, Centers for Disease Control and Prevention; the
Commissioner, Food and Drug Administration; the Administrator, Centers for
Medicare & Medicaid Services (formerly, Health Care Financing
Administration); and such additional officers of the U.S. Government that
the Secretary deems are necessary for the Committee to effectively carry out
its functions. CLIAC also includes a non-voting liaison representative who
is a member of AdvaMed (formerly, Health Industry Manufacturers Association)
and such other non-voting liaison representatives that the Secretary deems
are necessary for the Committee to effectively carry out its functions.
Due to the diversity of its membership, CLIAC is at times divided in the
guidance and advice it offers to the Secretary. Even when all CLIAC members
agree on a specific recommendation, the Secretary may not follow their
advice due to other overriding concerns. Thus, while some of the actions
recommended by CLIAC may eventually result in changes to the regulations,
the reader should not infer that all of the advisory committee's
recommendations will be automatically accepted and acted upon by the
Secretary.
|
CALL TO ORDER - INTRODUCTIONS/FINANCIAL DISCLOSURES
|
Dr. Toby Merlin, CLIAC Chair, welcomed the Committee members and called
the meeting to order. He reviewed the role of CLIAC and introduced Mr.
Kevin Malone, Attorney-Advisor, Office of General Counsel, CDC. Mr. Malone
explained the requirements and process for public disclosure, including
those for conflicts of interest. All members then made self-introductions
and financial disclosure statements relevant to the topics to be discussed
during the meeting.
Dr. Merlin welcomed four of CLIAC's newest members--Dr. Kathryn Foucar,
Dr. Cyril (Kim) Hetsko, Dr. Albert Stahmer, and Dr. David Sundwall. Dr.
Margaret Mary McGovern, another new Committee member, was unable to attend
the meeting.
Since this was the first anniversary of the tragic events of September
11, 2001, the Committee observed a moment of silence to reflect on the many
heroic efforts and loss of lives on that day.
|
|
AGENCY UPDATES
|
|
Food and Drug Administration (FDA)
Update
|
Addendum A |
Dr. Steven Gutman, Director, Division of Clinical Laboratory Devices,
Office of Device Evaluation, Center for Devices and Radiological Health (CDRH),
FDA, updated CLIAC on FDA activities. He reviewed FDA staffing changes and
plans to consolidate all premarket, compliance, and postmarket in vitro
device regulatory activities into a single functional unit, the Office of
In Vitro Diagnostic Evaluation and Safety. He also provided status reports
on several of CDRH's program activities, including the premarket review
processes and the CLIA test categorization program. Dr. Gutman discussed
FDA's strategic plan, which includes as one of its goals the total product
life cycle (TPLC), a new review process designed to ensure "cradle to
grave," seamless oversight of in vitro devices. Dr. Gutman pointed out the
510(k) review process has many limitations since it is based on the
equivalency of a new product to one on the market on or after 1976. He
stated that while the strengths of a premarket review include the Quality
Systems Regulation (QSR), which requires quality assessments, process
controls, and corrective actions, the limitations are that it only
provides a snapshot in time and the data submitted for the review are not
based on the actual performance of a product in the field. Dr. Gutman
explained the Food and Drug Administration Modernization Act (FDAMA),
encourages improved market access and increased interaction with industry
through a "least burdensome pathway" and a premarket to postmarket
balance. FDA's strategy to focus on TPLC, while still an evolving program,
will help to meet these goals.
Committee Discussion:
- Committee members expressed support for FDA's TPLC initiative.
- One member commented that FDA's law addressing the intended use of
products should require manufacturers of home-use products to submit
studies relating to their performance in all settings where they are
likely to be used, since products approved for home-use are automatically
waived under CLIA. Dr. Gutman agreed this topic warrants further
discussion.
- Members discussed the challenge of validating tests using analyte-specific
reagents (ASRs) and felt some manufacturers are abusing the ASR
regulation. For example, some manufacturers are reluctant to supply
reagent information to laboratories for validation studies, citing this
information is confidential. Frequently, a laboratory cannot obtain
materials, such as particular strains of bacteria or viruses, necessary to
validate their tests. One member stated genetic laboratories must do an
enormous amount of work to validate methods using ASRs. Dr. Gutman
responded the FDA is aware of this problem, but is unsure if regulatory
tools can address it. Basically, it is up to the laboratory to develop
quality assessment systems and act as a "mini FDA." Ms. Setzer pointed out
that the ASR regulation added current Good Manufacturing Practices (cGMPs)
to assure ASRs are manufactured consistently. Dr. Merlin acknowledged that
the inability to validate tests using ASRs represents a gap in safe and
accurate testing and noted the importance of CLIAC presenting this issue
to FDA and CDC.
- The Committee members noted that, as a result of bioterrorism
concerns, more clinical laboratories are performing environmental testing
and increasing numbers of environmental laboratories are performing
clinical testing. Although the Committee understands environmental testing
is not covered under CLIA, members pointed out that clinical decisions are
sometimes based on the results of this testing. Dr. Merlin suggested
documenting CLIAC's concern regarding appropriate oversight of
environmental testing to prevent potential public health problems. He
added, if such oversight is lacking, Congress should be informed that
legislation may be needed in this area. Members agreed, while
acknowledging that oversight can also be accomplished through voluntary
professional guidelines and established standards of practice.
|
Centers for Disease
Control and Prevention (CDC) Update
|
Towards a National Laboratory System
|
Addendum B |
Dr. Rex Astles, Division of Laboratory Systems (DLS), Public Health
Practice Program Office (PHPPO), CDC, began his presentation by describing
the current network of laboratories performing public health testing (e.g.,
testing for agents of bioterrorism, tuberculosis, HIV, blood lead, and
syphilis) as a loose association of public health, hospital, and independent
laboratories throughout the country, whose collaboration and communication
is often inconsistent and uncoordinated. He noted, although the perception
is that public health testing is performed in public health laboratories, in
reality, much of this testing is performed in clinical laboratories. Dr.
Astles reviewed the different roles for public health and private
laboratories and the need for an interdependent relationship in identifying
public health threats. In this regard, he explained, CDC's Office of
Laboratory Systems Development, within PHPPO, has developed strategic
initiatives with a goal to create a National Laboratory System (NLS)
consisting of a mutually collaborative network of public health and private
laboratories. These initiatives include utilizing professional
organizations, federal partners, and federally-funded state projects to
assess laboratory capabilities, address gaps in training, establish uniform
standards of laboratory practice, and improve collaboration of clinical
laboratories with state and local public health departments and CDC. Dr.
Astles then described demonstration projects in the states of Michigan,
Minnesota, Nebraska, and Washington, funded by the NLS and the Association
of Public Health Laboratories, which focus on various aspects of these
initiatives. Dr. Astles concluded by sharing plans for future activities and
the expected outcomes.
Committee Discussion
- One member inquired about plans to involve states that do not
currently have any clinical laboratory surveillance activities. Dr. Astles
stressed the importance of making these states aware of available tools
such as workable models and the national laboratory database created by
CDC, as well as the benefits of participating in the NLS. Another member
asked how data collection and reporting costs would be addressed. Dr.
Astles acknowledged these issues need to be addressed, possibly through
the development of more simplified data collection methods.
- Another member commented that at the Department of Health and Human
Services' (HHS) meeting on Strategic Planning for Homeland Security, the
American Society for Microbiology suggested the Laboratory Response
Network (LRN) be rolled into the NLS. Dr. Astles explained the two
programs serve different purposes. The LRN focuses on response to specific
events, whereas the NLS provides for a national system comprised of
private and public laboratories that would be supportive of any CDC
initiative, whether that be bioterrorism, foodborne disease, or other
outbreaks. This is accomplished by NLS proactively addressing training
needs, leadership development, and informatic integration of clinical
laboratories with public health laboratories.
- A member inquired if there were any initiatives at CDC to provide
training to laboratory directors. Dr. Martin replied that some activity
already exists in this area; DLS's National Laboratory Training Network
has developed training and educational materials in a variety of formats,
including CD-ROMs, videotapes, printed manuals, and electronic media,
which are available for loan to laboratory scientists.
- Members commended CDC for its leadership role in fostering
collaborations among public and private laboratories and encouraged
continuing its efforts to provide vital and up-to-date information to the
laboratory community.
|
Summary of
International Conference on Proficiency Testing for Medical Laboratories
- Global Odyssey 2002
|
Addendum C |
Dr. Joe Boone, DLS, PHPPO, CDC, presented a summary of the 2002 Global
Odyssey Conference, which was sponsored by CDC and held in Atlanta, Georgia
on February 24-26, 2002. He explained the objectives of this conference were
to explore advances in external quality assessment (EQA), to create global
opportunities for sharing and partnerships, and to promote the role of EQA
in global health. Approximately two hundred attendees from 54 countries
participated. Dr. Boone reviewed the conference outcomes, which included the
development of a global inventory of EQA programs, the creation of a website
for conference presentations, and the definition of seven postconference
workgroups. He shared a vision of improved communication, collaboration, and
global health as a result of international partnerships.
|
Quality
Institute Conference 2003
|
Addendum
D |
Dr. Joe Boone also presented plans for a
Quality Institute Conference to be held April 13-15, 2003, in Atlanta,
Georgia. The goals for this conference are to develop a framework for a
national report on the quality of laboratory services, to develop criteria
for quality indicators for laboratory services, and to develop a process
for ongoing data collection and analysis. The program for the conference
will involve representatives from diverse backgrounds, such as healthcare
providers, policy makers, laboratory professionals, accrediting and
standard setting groups, diagnostics industry, patient advocates, hospital
administrators, and payers/insurers. The conference will include plenary
sessions, workgroups, and posters. It is hoped an ongoing Quality
Institute will be created to foster better collaboration and coordination
between health laboratories and other parts of the healthcare system and
continuous data collection and analysis related to the quality of the
nation's health laboratory services.
Committee Discussion
- Members expressed support for the conference and asked whether efforts
were being made to involve hospital administrators, and if the conference
will qualify for CMEs, an incentive for physician participation. Dr. Boone
replied that plans include involving hospital administrators and to offer
CEUs, as well as CMEs.
- One member asked about Dr. Boone's statement that the conference will
be limited to 400 attendees, and commented there may be a greater demand
than this. Dr. Boone responded the limitation is due to the capacity of
available meeting space.
- Some of the members suggested patient safety relevant to laboratory
staffing shortages would be a relevant topic for the meeting.
|
Rapid HIV
Tests (CDC and FDA Updates)
|
Dr. Robert Martin, Director, DLS, PHPPO, CDC, provided a brief update on
the status of and issues surrounding rapid HIV tests. Recently, two
manufacturers announced that they have rapid HIV tests in FDA's premarket
approval process. Dr. Martin commented that several advocacy groups see
widespread access to these tests as pivotal in reducing the incidence of HIV
infection, especially in hard-to-reach high-risk populations. In addition,
they believe this access can only be attained if the tests are waived when
they have been cleared for marketing. However, other groups are concerned
that test quality will suffer and the public's health will be compromised if
the tests are waived. Dr. Martin noted the challenge of assuring access to
rapid HIV testing while maintaining test quality, and reviewed the
recommendations made by FDA's Blood Products Advisory Committee (BPAC) and
the Presidential Advisory Council on HIV and AIDS (PACHA). At its June 14,
2001 meeting, BPAC voted unanimously against waiving rapid HIV tests from
CLIA oversight. This vote occurred after CMS presented data from a pilot
study in which on-site inspections of a number of laboratories performing
waived tests identified significant testing problems, most notably, failure
to follow manufacturers' test system instructions. In contrast, PACHA
recommended that rapid HIV tests be waived after representatives from the
National Alliance of State and Territorial AIDS Directors presented a
statement to the Council at its June 21, 2002, meeting, citing the need for
waiver to assure widespread access and reduce HIV infections. Dr. Martin
informed the Committee members that a CDC Consultation Meeting on the
implementation of rapid HIV testing was being held concurrently with this
CLIAC meeting and efforts were underway to educate all involved on the
existing options for addressing both sides' concerns. However, he
acknowledged that these issues are complex and that some options may not be
workable in all states due to individual state laws. He pointed out that
developing countries with a higher prevalence of HIV than the United States
offer rapid HIV testing, but rapid testing is implemented in these settings
with appropriate training, quality assurance (QA), proficiency testing (PT),
and oversight.
Committee Discussion
- A Committee member stated that in his experience as a physician
treating HIV patients, many people at high risk for HIV infection do not
want to know their status or change their behavior and thus, do not enter
into treatment. He conveyed the American Medical Association (AMA) does
not agree with waiving a rapid HIV test in the absence of sufficient data.
This member provided the Committee with a copy of a letter to HHS
Secretary Tommy Thompson, co-signed by the AMA and the American
Association of Bioanalysts, stating these tests should not be waived
Addendum E.
- One member pointed out the CLIA requirements for waiver specify that a
waived test be robust, with low risk of harm if performed incorrectly; an
incorrect HIV test result would have significant consequences and not meet
the risk of harm criterion for waiver. Also, home-use testing by third
parties is a concern and illustrates the problem with the statutory
language which requires tests cleared for over-the-counter use to be
automatically waived. This member suggested professional organizations
work with their Congressional liaisons to pursue legislative changes to
the CLIA statute. Another member agreed, commenting these issues will not
go away and legislative correction is needed.
- Another member commented that while the analytic phase of rapid HIV
testing may be simple, the pre- and postanalytic phases, including patient
counseling, are critical. In particular, data shows that up to 20 percent
of HIV tests are false positives and confirmatory testing is sometimes not
performed. Patient stress due to positive results can be great, resulting
in severe depression and other adverse reactions. The Committee member
cautioned that if a rapid HIV test is waived without considering the pre-
and postanalytic phases, it may set a precedent for waiving other tests
with significant pre- and postanalytic issues such as genetic tests. This
member pointed out that, under CLIA, a limited public health certificate
would allow access to moderate complexity rapid HIV testing in
nontraditional sites while assuring minimum requirements for QA, PT, and
training are met. Another member agreed, and emphasized QA, PT, and
training will not occur unless they are required.
- Dr. Martin summarized the difficulty in determining the appropriate
level of CLIA oversight for rapid HIV tests. Some groups don't believe the
tests should be waived because there would be no regulation of these
tests, but they also do not believe categorizing them as moderate
complexity is appropriate. He questioned whether there is a need to create
a new category for tests of public health significance.
Dr. Elliot Cowan, Office of Blood Research and Review, Center for
Biologics Evaluation and Research, FDA, updated the Committee on the
progress made toward the FDA premarket approval of rapid HIV tests since the
last CLIAC meeting (Addendum F).
He reminded the Committee that FDA is prohibited from releasing any
information related to manufacturers' premarket approval submissions, as
this is considered proprietary and any discussion of a submission's status
is limited to discussion of public information only, or information
authorized for release by the applicant. He then informed the Committee that
MedMira, Inc. has permitted FDA to disclose it has received an "approvable"
letter from FDA for its Reveal™ Rapid HIV Test. Dr. Cowan also informed the
Committee that OraSure Technologies, Inc. publicly announced it has received
an "approvable" letter for its OraQuick Rapid HIV-1 Antibody Test. Final
marketing approval for each test is subject to the manufacturers meeting
conditions imposed by FDA. OraSure Technologies has announced they plan to
seek waiver approval for the OraQuick Rapid HIV-1 Antibody Test once it
receives final FDA marketing approval.
Dr. Tom Hearn, Deputy Director, DLS, PHPPO, CDC, gave an overview of the
CDC Consultation Meeting proceedings. He explained the purpose of the
meeting was to provide a forum for the interchange of viewpoints on rapid
HIV testing issues. As background, Dr. Hearn pointed out that CDC has a
5-year HIV prevention strategic plan with a goal to reduce HIV infection by
50 percent and, to reach this goal, there is a need to increase the number
of people tested. He also explained that two Centers and one Office within
CDC have specific interests in HIV testing: the National Center for HIV,
STD, and TB Prevention (NCHSTP); the National Center for Infectious Diseases
(NCID); and PHPPO. NCHSTP works with a variety of partners on public health
surveillance, prevention research, and programs to prevent and control HIV.
NCID conducts basic and applied studies to better understand and detect HIV
infection. PHPPO focuses on the quality processes and systems essential to
the public health system. Dr. Hearn reported that HHS is aware of the debate
about waiver for the new rapid HIV tests. An interagency HHS task force has
been meeting by teleconference for the purpose of having a discussion among
the agencies and Department about the key issues and data around this
debate. Dr. Hearn encouraged CLIAC members and organizations that have
relevant data to share it with CDC and HHS to help inform decision-making.
Committee Discussion
- Members reiterated their concerns with waiving rapid HIV tests (At the
Committee's May 2001 meeting, it recommended that rapid HIV tests not be
waived). Members noted that data and information presented by CMS and
others indicate incorrect performance of waived testing may result in
incorrect test results. One member again commented there is not a test for
HIV that renders negligible an erroneous result for the patient.
- Members agreed the perceived urgency to waive rapid HIV tests is not
based on data, but by concerns of promoting access. They also expressed
concern that no data is currently available on how well these tests might
perform if waived. The members emphasized the necessity of considering the
pre- and postanalytic issues surrounding this testing and further
recommended that a decision on whether to waive rapid HIV tests not be
made until objective data are available on their performance in a waived
setting.
- The Committee unanimously voted to send a letter to Secretary Thompson
recommending that appropriate oversight, training, QA, QC, and PT are
required for even the simplest HIV testing device (Addendum G).
Although the members support making HIV testing widely accessible, CLIAC
does not believe the waiver category is appropriate for these tests at
this time and suggests that existing mechanisms, such as the limited
public health certificate exception under CLIA, will allow these tests to
be used without compromising public health.
|
Centers for
Medicare & Medicaid Services (CMS) Update
|
Addendum
H
|
Ms. Judy Yost, Director, Division of Outcomes and Improvement, Center for
Medicaid and State Operations, CMS, provided an update on CMS's recent CLIA
activities and laboratory statistics as of January 2002. This included
information and data from CMS's Waived Laboratory Survey Project. She
explained that while studies by CMS and others indicate 50 percent of waived
laboratories have quality problems, they also show compliance is maintained
75 percent of the time when education is provided. As a result of these
findings, beginning April 15, 2002, CMS initiated a three-year study in
which each state will evaluate 2 percent of waived laboratories each year.
In addition, Ms. Yost noted that CMS is working with manufacturers to
improve the clarity of their test system instructions and is compiling a
"clearinghouse" of existing educational programs for waived testing, which
will be added to the CMS CLIA website. She also mentioned some of the other
information available on the CMS CLIA website (www.cms.hhs.gov/clia/),
such as special alerts; the 2001 Laboratory Registry that lists the names of
laboratories receiving CMS sanctions and any related hearing decisions; CMS
Regional Office contacts; and CLIA-approved proficiency testing program
providers. In closing, Ms. Yost briefly discussed the re-approval of the
Department of Defense's laboratory oversight program, the Secretary's
Regulatory Reform Initiative's draft recommendations relative to CLIA, and
the status of the final quality control regulation and the waiver
regulation.
Committee Discussion
- One member questioned whether the Waived Laboratory Survey Project was
a study of randomly-selected laboratories. Ms. Yost confirmed that while
the sample of laboratories was randomly selected, efforts were made to
include both urban and rural laboratories, as well as large volume and
small volume laboratories.
- Another member, while pleased that the study was capturing information
relative to waived test performance and patient outcomes, expressed
continuing concern about the use of tests approved for home use in
clinical settings. Ms. Yost replied that the CLIA statute provides for an
automatic waiver of tests approved for home use, but does not address
intended use. She suggested, as an alternative, monitoring the postmarket
performance of these tests. Dr. Gutman clarified that the real issue is
the incongruence between the laws, the FDA law pertaining to premarket
clearance of tests for home use and the CLIA law, which was revised in
1997 to automatically waive tests approved by the FDA for home use. While
Dr. Gutman acknowledged the Committee's concern, he noted that changes in
the law require Congressional legislation.
- Ms. Setzer requested an update on the inspection data for moderate and
high complexity laboratories. Ms. Yost replied the decrease in the number
of moderate and high complexity laboratories makes it hard to compare data
from survey cycle to survey cycle. However, she noted that while the top
four deficiencies cited remain the same, the number of laboratories having
problems has decreased.
|
PRESENTATIONS AND COMMITTEE DISCUSSIONS
|
Coordinating Council on the Clinical
Laboratory Workforce (CCCLW) April 2002 Summit Meeting Report to
CLIAC
|
Addendum I |
Ms. Cynthia Johns, Laboratory Manager,
Colorado Coagulation Esoterix, Inc. and CLIAC member, reported on the April
2002 summit meeting of the CCCLW, previously known as the Summit on
Laboratory Workforce Shortage. She presented an overview of the CCCLW
strategic plan with associated goals and activities developed to address
laboratory workforce shortages. She described the Council's various
workgroups; summarized the completed, in-progress, and future activities of
each workgroup; and identified the lead laboratory professional organization
responsible for facilitating each workgroup activity. Ms. Johns reported
that continuous communication among workgroups, professional organizations,
and the steering committee was critical to accomplishing the Council's
goals.
|
CCCLW Activity - Update
since April 2002
|
Addendum J |
Dr. Brenta Davis, Chairman, Department of Clinical Laboratory Sciences,
University of Tennessee-Memphis and CLIAC member, updated the Committee on
the activities of the CCCLW workgroups since the April 2002 summit meeting.
She reviewed current data on the status of clinical laboratory educational
programs and workforce salaries, announced the recognition of CCCLW as a
focal point for laboratory workforce information and action, and described
several laboratory career promotional projects targeting high school and
college students. She concluded her presentation with a request that CLIAC
continue to: (1) voice concern about the laboratory workforce shortage and
its significance to the healthcare community and government; (2) participate
in and support CCCLW activities; and (3) participate in other meetings and
informational sessions about workforce issues.
Committee Discussion
- Committee members acknowledged the critical workforce shortage in the
clinical laboratory and noted that similar shortages exist in all fields
of healthcare. When asked whether current data identifies deterrents to
choosing a career in laboratory medicine and to retaining laboratory
staff, Dr. Davis and Ms. Johns responded increased stress in the work
place, competing career choices that are more lucrative, and lack of
professional image are significant deterrents. When asked how to attract
former laboratory workers back to the field, Ms. Davis replied that
workers who leave the field do not return; however, continuing and
re-education programs have not been fully utilized.
- Dr. Merlin suggested more data is needed to link salaries with the
quality of healthcare workers and patient outcomes.
- CLIAC lauded the united effort of professional organizations and the
success of the CCCLW activities over the last two years. The members also
acknowledged the continuing need for coalitions of professional
organizations and healthcare communities to market the laboratory
profession and address workforce shortage issues.
|
Healthcare Workforce
Issues
|
Addendum K |
Dr. Rumay Alexander, President and CEO, The Roxie Company, representing
the American Hospital Association (AHA), defined the current shortages of
all categories of hospital workers as a "looming crisis in care" and a
"long-term problem that will become worse with time." She reviewed the AHA's
2001 hospital data showing continuing increases in vacancy rates and
difficulty in recruitment and retention of hospital workers. Dr. Alexander
then discussed the January 2001 establishment of the AHA Commission on
Workforce for Hospitals and Health Systems, of which she was a member, to
address both the identified causes and solutions for workforce shortages.
Dr. Alexander's presentation concluded with a summary of the Commission's
April 2002 report, In Our Hands - How Hospital Leaders Can Build a Thriving
Workforce, noting the report can be found on AHA's website:
www.hospitalconnect.com/aha/key_issues/workforce/commission/InOurHands.html.
The report includes a strategic plan and recommendations to hospital
leaders, local communities, professional organizations, and educators on
immediate and sustained activities needed to reverse the workforce shortage
and to establish a strong foundation for our healthcare's future.
Committee Discussion
The Committee applauded the efforts of AHA and supported the Commission's
recommendations for improving the healthcare workforce environment, in
recognizing the need for a more diverse workforce, and in supporting
healthcare career initiatives that target the educational system and provide
incentives for choosing a career in healthcare.
|
Sentinel Event Data
and Staffing Effectiveness
|
Addendum L |
Ms. Joanne Born, Executive Director, Laboratory Program, Joint Commission
on Accreditation of Healthcare Organizations (JCAHO), described the JCAHO
accreditation program as promoting patient safety and performance
improvement through a process that includes a professionally-derived
standards of compliance survey and a sentinel events voluntary
self-reporting system. (A sentinel event is defined as any unexpected
occurrence involving death or serious physical or psychological injury or
the risk thereof.) She summarized current data from the JCAHO sentinel
events database, including types of events reported, settings where events
occur, and the root causes of the events. She noted that communication
problems are responsible for 63 percent of all reported events, with
orientation and training issues the second most commonly identified cause
(53 percent). JCAHO has been concerned with the shortage of qualified
professional personnel and the sentinel events data do identify linkages
between staffing effectiveness and patient safety. In this regard, Ms. Borne
pointed out that various problems related to staff training and competency
have ranked in the top 5 laboratory compliance issues over the last 3 years.
She concluded her presentation by summarizing the findings of a national
panel of experts, representing various settings and disciplines, charged
with analyzing staffing models and identifying indicators that could be used
as effective screening tools for staffing issues in future JCAHO compliance
surveys.
Committee Discussion
- In response to several questions regarding the sentinel events
database, Ms. Born informed CLIAC members the database is accessible on
the JCAHO website. Several members expressed concern that voluntary
self-reporting of sentinel events would result in under-reporting. Ms.
Born concurred, but stressed that even with under-reporting, if
institutions effectively use the process of root cause and analysis
internally, errors can be averted, resulting in the absence of a sentinel
event to report.
- Members discussed the pros and cons of deemed status organizations
implementing unannounced inspections. A majority of members recognized the
advantages of unannounced inspections, but agreed that current staffing
shortages would make it difficult for laboratories to meet both patient
care service needs and the demands of an unannounced on-site inspection.
- The JCAHO laboratory accreditation process was discussed, with members
specifically inquiring about JCAHO formats for evaluating laboratory
validation of new methods, staffing models, and the impact of the Health
Insurance Portability and Accountability Act of 1996 (HIPAA) on the
accreditation process. Ms. Born explained that JCAHO has always addressed
patient confidentiality issues in its process, has standards that are used
for evaluating how a laboratory validates new methods, utilizes a
certification examination to qualify its site surveyors, and expects the
healthcare organization to have policies that address the services it
provides and the staff needed to deliver those services.
- The discussion concluded with all members agreeing performance
improvement is a very important part of the JCAHO accreditation process,
sentinel events reporting is an effective tool for measuring the quality
of a healthcare delivery system and, in particular, capturing data
relating laboratory services to patient outcomes is essential and very
much needed.
|
Congressional Activities
Update - Legislative Solutions to the Laboratory Workforce
|
Addendum M |
Ms. Robin E. Strombler, Vice President, Government Affairs, American
Society for Clinical Pathology (ASCP), identified laboratory budget issues
and educational incentives as critical factors impacting laboratory
workforce retention and attraction of professionals to both laboratory
medicine and underserved communities. She summarized current legislative
actions affecting laboratory budgets and reported on the status of allied
health project grants, citing the implementation of four laboratory training
sites in rural Nebraska as a project grant success story. She then reviewed
the findings of the ASCP Board of Registry and Morpace Wage and Vacancy
Survey of March 2001, listed ASCP's additional workforce shortage concerns,
and discussed the content of HR 1948, the Medical Laboratory Personnel
Shortage Act of 2001 and two provisions included in the Bioterrorism
Preparedness and Response Act of 2002. Ms. Strombler ended her presentation
by soliciting CLIAC to encourage HHS to address workforce shortage issues in
clinical and public health laboratories as part of its strategic plan goal
to enhance the ability of the nation's healthcare system to effectively
respond to bioterrorsim and other public health challenges. The associated
strategy should include educational funding as a mechanism for facilitating
a competent and adequate workforce.
Committee discussion was deferred until the completion of Dr. Atul
Grover's presentation on Laboratory Workforce Analysis Activities.
|
Laboratory
Workforce Analysis Activities - Clinical Laboratory Workers
|
Addendum N |
Dr. Atul Grover, Chief Medical Officer, National Center for Health
Workforce Information and Analysis, Bureau of Health Professions, Health
Resources and Services Administration (HRSA), began his presentation by
reviewing the mission and functions of the National Center for Health
Workforce Information and Analysis and the Bureau of Health Professions. He
then gave an overview of the products and activities of the Center, both
nationally and regionally, including an 18-state comprehensive health
workforce profiles project. Dr. Grover summarized the trends, issues, and
supply and demand projections for the healthcare workforce and discussed the
impact of changing demographics on the requirements for healthcare
providers. He also reviewed ASCP 2000 and 2001 survey data on clinical
laboratory training programs; the 1994-2000 trends in vacancy rates for
selected laboratory personnel; and the Bureau of Labor Statistics' data of
mean annual salaries for medical technologists and medical laboratory
technicians. Dr. Grover highlighted some of the factors affecting the
laboratory labor market, reasons for increased demand for laboratorians, and
potential causes for staffing shortages. He concluded by identifying
barriers to addressing laboratory worker shortages and presenting key
questions that will be addressed in a 2003 HRSA-funded Clinical Laboratory
Sciences Personnel Shortage Study.
Committee Discussion
- Several members voiced concern about funding sources needed for
medical education programs and asked if student financial aid was
addressed in the two provisions of HR 1948 included in the Public Health
Security and Bioterrorism Preparedness and Response Act. Ms. Strombler
indicated the Act has provisions for low interest loans and partial
scholarships and there is a possibility that it may provide for loan
forgiveness programs at the state and local level.
- The importance of establishing partnerships between healthcare
providers and educators and the funding of training programs in
non-traditional settings were then discussed, with members agreeing that
without increased resources available to healthcare institutions and
education and training programs, the number of programs and access to
continuing medical education will continue to decrease. Several members
asked for clarification on California bill SB 1809, recently signed into
law, addressing laboratory workforce shortages in California. Ms.
Strombler and Dr. Ng, a CLIAC member from California, stated SB 1809
creates a new California license category for a medical laboratory
technician (MLT), explaining that current California law does not
recognize the MLT. They noted that while the California has enacted the
law, regulations implementing the provision have not yet been developed.
- One member commented that advances in technology combined with
laboratory workforce shortages made for a driving force, increasing the
demands for point-of-care and waived testing, and are changing the spectra
of the workforce. Several members agreed, noting the broadening scope of
practice will require appropriate standards of practice to maintain
quality and assure minimal competency of testing personnel. One member
asked if there are objective data linking state personnel licensure
requirements to higher levels of competency in testing personnel. Dr.
Grover responded that the Center currently lacks sufficient resources to
collect data linking objective measures to outcomes. Members again
reiterated the need for funding of educational programs and studies that
link objective data to patient outcomes.
- A final discussion centered on laboratory workforce shortages and
salaries, with one member reminding the Committee that without changes in
current reimbursement regulations, salaries will not increase and the
laboratory workforce will continue to decrease.
|
Genetic
Testing
|
Secretary's Advisory Committee on Genetic
Testing (SACGT) Meeting Report
|
Addendum O |
Dr. Patricia Charache, CLIAC and SACGT member, informed the Committee
that SACGT's charter expired in August 2002. She summarized the activities
and accomplishments of SACGT, particularly regarding its recommendations for
enhancing the oversight of genetic tests through proposed FDA
responsibilities, CLIA provisions for genetic testing, and postmarket data
collection. Dr. Charache reviewed SACGT's definitions for analytical
validity, clinical validity, and clinical utility, and its proposed
oversight for transition of genetic tests from research phase to clinical
use. Her report highlighted activities of SACGT workgroups and task forces
on education, informed consent and institutional review boards (IRBs), rare
disease testing, access, and data collection. Dr. Charache also summarized
SACGT's additional concerns and outstanding issues, including pre- and
postanalytic considerations of waived tests, gene patenting and licensure,
provision of education/guidance documents for IRBs and research laboratories
interested in providing patient care, oversight of laboratory-developed
tests, informed consent procedures relative to requests for genetic testing,
reimbursement for laboratory expenses associated with obtaining necessary
information regarding genetic test orders, and education of laboratory
personnel specific to genetic testing. |
|
Molecular Genetic Test Orders
|
Addendum P
|
Ms. Kathy LaBeau from the Washington State Department of Health and
Network Director, Pacific Northwest Laboratory Medicine Sentinel Monitoring
Network, presented a summary of molecular genetic testing in Washington
State and the Pacific Northwest region: the types of tests being ordered,
where the tests are performed, and the reasons/criteria for choosing the
laboratory to perform the testing. This information was collected via a
survey of laboratories performing moderate and high complexity testing in
the Network from October through December 2001.
Committee Discussion on Presentations by Dr. Charache and Ms. LaBeau
- Several Committee members voiced concern
about the use of exclusive patents for some genetic tests, noting that
this practice could become more widespread in the future causing a variety
of testing and access issues. One Committee member pointed out that recent
National Institutes of Health (NIH) grants to commercial laboratories for
test development have prohibited the use of exclusive patents. Dr. Merlin
suggested that because of the Committee's concern about the use of
exclusive patents and the impact they may have on access to and quality of
genetic testing, the issue be further reviewed and discussed at a future
Committee meeting or by other committees in another forum.
- One Committee member questioned whether CLIAC's recommendations and
proposed definition for genetic tests would be applicable to
pharmacogenetic testing, which is usually performed to determine
individual response to medicine rather than for assessment of disease and
health conditions. Several members responded that the proposed definition
of molecular genetic testing would include analysis of human DNA or RNA to
detect heritable or acquired disease-related genotypes, mutations, or
phenotypes, and pharmacogenetic tests would meet this proposed definition.
As well, the Committee's recommendations relative to the quality control
and quality assurance of genetic testing would also be appropriate for
pharmacogenetic tests.
- Several Committee members inquired about the timeframe for developing
the proposed rule that would revise the current CLIA regulations to
include specific requirements for genetic testing. Ms. Rhonda Whalen,
Chief Laboratory Practice Standards Branch, DLS, PHPPO, CDC, responded
that a regulatory impact analysis for the proposed rule is in development;
however, the timeframe for publishing the Notice of Proposed Rule Making (NPRM)
can not be determined at this time because of other regulations currently
under development and in clearance.
- One Committee member expressed concern about the length of time for
developing the NPRM and inquired whether the Committee could provide help
on data collection for the regulatory impact analysis.
- Committee members commented that the terms analytical validity,
clinical validity, and clinical utility are not well understood and need
to be better defined. They suggested voluntary practice guidelines and
laboratory standards developed by professional organizations, such as the
College of American Pathologists and the American College of Medical
Genetics, might be helpful in defining these validation criteria for
genetic tests. Dr. Charache responded that genetic test validation is an
extremely complex issue and postmarket validation data for these tests are
currently being evaluated by a CDC project under the direction of Dr. Muin
Khoury, Director of Office of Genomics and Disease Prevention, National
Center for Environmental Health, CDC. One Committee member suggested
inviting Dr. Khoury to present results of this evaluation project at a
future CLIAC meeting.
|
Public Comment
|
Mr. Phil Bongiorno, Assistant Director, Public Health and Scientific
Affairs, College of American Pathologists (CAP), informed CLIAC of two
pieces of legislation endorsed by CAP that may address some of the
Committee's concerns relative to exclusive gene patents: the 'Genomic
Science and Technology Innovation Act of 2002' (HR 3966) and the 'Genomic
Research and Diagnostic Accessibility Act of 2002' (HR 3967).
|
Adjourn
|
Before adjourning the meeting, Committee members voted on dates
for two CLIAC meetings in 2003. The agreed upon dates are March 12-13,
2003, and September 17-18, 2003.
Dr. Merlin adjourned the meeting.
I certify that this summary report of the September 11-12, 2002, meeting
of the Clinical Laboratory Improvement Advisory Committee is an accurate and
correct representation of the meeting.
|
/S/ Toby Merlin, M.D., CLIAC Chair |
Date: 12/4/2002 |
This page last reviewed: 7/12/2004
|
|